Morgan Stanley Call 200 BGNE 20.0.../ DE000ME9RY79 /
| 6/3/2024 8:23:42 PM | Chg.- | Bid12:08:57 PM | Ask12:08:57 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.720EUR | - | 0.640 Bid Size: 1,000 |
1.020 Ask Size: 1,000 |
BeiGene Ltd | 200.00 USD | 9/20/2024 | Call |
GlobeNewswire
5/28
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study
GlobeNewswire
5/14
SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
5/2
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
GlobeNewswire
5/2
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business...
GlobeNewswire
4/11
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
GlobeNewswire
3/28
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire
3/28
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlight...
GlobeNewswire
3/5
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the ...
GlobeNewswire
2/27
MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor
GlobeNewswire
2/27
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights ...
GlobeNewswire
2/8
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
